+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PTC Therapeutics - logo

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

From
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • September 2024
  • 1150 Pages
  • Global
From
From
From
From
Cystic Fibrosis Devices - Global Strategic Business Report - Product Thumbnail Image

Cystic Fibrosis Devices - Global Strategic Business Report

  • Report
  • November 2024
  • 93 Pages
  • Global
From
High-Grade Glioma - Pipeline Insight, 2024 - Product Thumbnail Image

High-Grade Glioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 200 Pages
  • Global
Diffuse Intrinsic Pontine Glioma - Pipeline Insight, 2024 - Product Thumbnail Image

Diffuse Intrinsic Pontine Glioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Glioma - Pipeline Insight, 2024 - Product Thumbnail Image

Glioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 450 Pages
  • Global
From
Rare Disease Treatment Market Report and Forecast 2023-2031 - Product Thumbnail Image

Rare Disease Treatment Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Loading Indicator